Prevention of stricture formation after endoscopic sclerotherapy of esophageal varices.
In order to evaluate the effectiveness of an intensive acid protection regimen in preventing sclerotherapy-associated esophageal strictures, 62 patients undergoing sclerotherapy were randomized to receive either acid protection (antacids, cimetidine, and sucralfate) or no acid protection. Of 31 patients (38.7%) in the no acid protection group, 12 developed a symptomatic stricture during the course of sclerotherapy compared with 3 patients (9.7%) in the group assigned to acid protection (p less than 0.01). Our study demonstrates that a vigorous acid protection regimen will help prevent symptomatic esophageal strictures associated with variceal sclerotherapy.
Snady
H
H
Section of Gastroenterology, VA Medical Center, Bronx, New York.
Rosman
A S
AS
Korsten
M A
MA
D000863:Antacids / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use*; D004940:Esophageal Stenosis / Q000209:etiology / Q000517:prevention & control*; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000628:therapy*; D004945:Esophagoscopy; D005069:Evaluation Studies as Topic; D005233:Fatty Alcohols / Q000627:therapeutic use*; D006801:Humans; D008108:Liver Diseases, Alcoholic / Q000150:complications; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D015911:Sclerotherapy / Q000009:adverse effects; D012981:Sodium Tetradecyl Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D013392:Sucralfate / Q000627:therapeutic use*
D000863:Antacids; D005233:Fatty Alcohols; D013392:Sucralfate; D002927:Cimetidine; D012981:Sodium Tetradecyl Sulfate